L

Lineage Cell Therapeutics
D

LCTX

0.84310
USD
0.02
(1.85%)
Market Closed
Volume
6,260
EPS
0
Div Yield
0
P/E
-6
Market Cap
159,208,791
OverviewSignalsIdeasNews
Related Instruments
    B
    BIIB
    -2.500
    (-1.17%)
    210.710 USD
    C
    CRSP
    -2.450
    (-4.28%)
    54.840 USD
    E
    EDIT
    -0.28500
    (-5.26%)
    5.13500 USD
    NVS
    0.650
    (0.58%)
    112.100 USD
    R
    RARE
    -0.870
    (-1.93%)
    44.140 USD
    S
    SGMO
    -0.09690
    (-12.11%)
    0.70340 USD
    S
    SRPT
    1.650
    (1.16%)
    144.000 USD
    V
    VYGR
    -0.59000
    (-6.37%)
    8.67000 USD
    W
    WVE
    -0.46000
    (-6.95%)
    6.16000 USD
News

Title: Lineage Cell Therapeutics

Sector: Healthcare
Industry: Biotechnology
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.